Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FSC231
- Development stage
- Preclinical
- Lead developer
- scPharmaceuticals
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
FSC231 is a subcutaneous formulation of iron isomaltoside, developed by scPharmaceuticals. It is designed for the treatment of iron deficiency anemia, offering a subcutaneous administration route for a therapy previously limited to intravenous delivery. The drug aims to replenish iron stores in patients with iron deficiency.
- Brand names
- MonoferMonoferric
- Other names
- ferric derisomaltoseiron isomaltoside 1000
02
Targets
PICK1 (Protein interacting with C kinase 1)
Beyond the preview
Go deeper on FSC231.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FSC231.